YIM Program Agenda

YIM Program

One of the goals of the iwCLL is to promote the development of emerging scientists, both clinic- and laboratory-based, who will continue to unravel outstanding questions in CLL. Since 2005, iwCLL has been preceded by a Young Investigator Meeting (YIM), which offers an opportunity for investigators less than 40 years of age to present and discuss their data.

The YIM is a forum for tomorrow’s leaders to network and collaborate with today’s CLL experts. Because of its relaxed atmosphere that facilitates interaction between emerging and established leaders in CLL,

“The purpose of the YIM is to facilitate the professional development of young clinical scientists in the field of CLL research. By providing an opportunity for young investigators to share their research interest in CLL, the YIM planners hope to promote their participation in the iwCLL and encourage their interaction with established senior CLL scientists and investigators to help advance their careers.”

–Shih-Shih Chen, PhD; 2019 YIM Co-Chair

Friday, 20 September
07:30
Breakfast Tea & Coffee
08:00 Welcome and Introductions
08:05
Session 1: CLL Biology and Translational Research
Chair(s): Talha Munir, Matthew Davids
08:10 2049/2205: Analyzing the mutational landscape of two CLL mouse models overexpressing AID identifies proliferative fraction-associated tumor genes involved in leukemic development and progression
Pablo Morande
08:25 2168: Comparison of Genomic Complexity Risk Stratification by Chromosome Banding Analysis and Genomic Microarrays in CLL Patients With Complex Karyotype
Silvia Ramos
08:40 2011: Characterization of therapeutic resistance in chronic lymphocytic leukemia using functionalized lineage tracing
Catherine Gutierrez
08:55 2164: Therapeutically inducing interferon signaling in T cells with avadomide enhances the efficacy of anti-PD-L1/PD-1 immunotherapy in chronic lymphocytic leukemia
Nikolaos Ioannou
09:10 2020: Ikzf3 mutation dysregulates B cell receptor signaling and migratory responses in a conditional knock-in mouse model
Elisa ten Hacken
09:25 2074: Functional evaluation and mechanism study of circ-RPL15 as a plasma biomarker and novel oncogenic driver to promote progression of chronic lymphocytic leukemia
Hui Jin
09:40 2060: Combined ibrutinib and venetoclax changes myeloid immune phenotype and improves immune function in CLL patients
Eva Rebecka Svanberg
09:55 Morning Break
10:20
Session 2: Clinical Research
Chair(s): Othman Al-Sawaf, Philip Thompson, Nitin Jain
10:25 2064: The Role of 18F-FDG-PET in Detecting Richter’s Transformation of Chronic Lymphocytic Leukemia in Patients Receiving Therapy with a B-cell Receptor Inhibitor
Yucai Wang
10:40 2117: Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia
Paul Hampel
10:55 2134: Second primary malignancies (SPM) and Richter’s transformations in treated and untreated patients with chronic lymphocytic leukemia (CLL): an analysis of the registry of the German CLL Study Group (GCLLSG)
Moritz Fürstenau
11:10 1941/2206: Pneumocystis jirovecii pneumonia and invasive fungal infection incidence and institutional prophylaxis practices in CLL patients treated with BTK inhibitors
Christine Ryan
11:25 2056: Minor mutations in TP53 associate with shorter PFS but not OS after chemoimmunotherapy – Results from the Complement2 trial
Eugen Tausch
11:40 2089/2207: Undetectable Minimal Residual Disease Should be the Goal of Venetoclax Therapy in Relapsed and Refractory Chronic Lymphocytic Leukaemia
Thomas Lew
11:55 Lunch
CONCURRENT BOOTCAMP SESSIONS
Basic Biology Investigator Bootcamp
Chair(s): Ingo Ringshausen, Shih-Shih Chen, Nicholas Chiorazzi
13:00 Poster Presentations From the Podium
2083: Gene Expression and Cytokine Analyses Identify Markers of Progression from MBL to CLL
Gonzalo Blanco
2095: Dissecting the role of Toll-like receptors induced IkBz over-expression in Chronic Lymphocytic Leukemia
Ilenia Sana
2193/2208: IL10-producing CD38hi B-regulatory cells drive the immunosuppressive microenvironment in CLL and can be targeted with anti-CD38 immunotherapy
Alak Manna
2200: Chronic lymphocytic leukemia cells impair mitochondrial fitness in T cells which can be rescued by CD40-stimulation of the CLL cells
Fleur Peters
2096/2209: CD8+ T-cell exhaustion induced by leukemic cells mediates progression in Chronic Lymphocytic Leukemia (CLL)
Isabel Jiménez
13:20 Roundtable Discussion
14:05 Career Development Discussion
14:45 Afternoon Break
Translational Investigator Bootcamp
Chair(s): Talha Munir, Matthew Davids
13:00 Poster Presentations From the Podium
2009: Pevonedistat, a NEDD8-activating enzyme (NAE) inhibitor, is a favorable modulator of T-cell function in ex vivo studies of chronic lymphocytic leukemia (CLL)
Scott Best
2099: Mass cytometry analysis of B cell receptor signalling in normal B and chronic lymphocytic leukaemia cells in peripheral blood
Faten Yasin
2167: AID and LPL mRNA expression are useful additional markers that improve CLL-IPI prediction in progressor patients
Angimar Uriepero
2062/2210: Distinct Immune Signatures in Chronic Lymphocytic Leukemia and Richter Syndrome
Yucai Wang
1931: Overexpression of TCTP Induces Inferior Prognosis and Fludarabine-Resistance in Patients with Chronic Lymphocytic Leukemia
Rui-ze Chen
13:20 Roundtable Discussion
14:05 Career Development Discussion
14:45 Afternoon Break
Clinical Investigator Bootcamp
Chair(s): Othman Al-Sawaf, Philip Thompson, Nitin Jain
13:00 Poster Presentations From the Podium
1999: Use of antibiotics and risk of chronic lymphocytic leukemia: a population-based case-control study
Michael Asger Andersen
2082: Impact of Individual Comorbidities on Mortality and Causes of Death in Chronic Lymphocytic Leukemia
Emelie Curovic Rotbain
2118: A novel simplified comorbidity score for chronic lymphocytic leukemia (CLL): a large multicenter retrospective cohort study of patients treated with ibrutinib and/or chemo-immunotherapy (CIT)
Max Gordon
2054: Role of complex karyotype (CK) in patients with chronic lymphocytic leukemia (CLL): A systematic review and meta-analysis.
Irbaz Bin Riaz
1990: Characteristics and Outcomes of Ibrutinib-Associated Musculoskeletal Toxicities in CLL Patients
Joanna Rhodes
13:20 Roundtable Discussion
14:05 Career Development Discussion
14:45 Afternoon Break
15:00 Keynote
Presentation: Career Development
John Seymour
15:45 Q & A
16:00 The Epigenetic Features of CLL:
DNA Methylation
Christoph Plass
16:15 Adjourn

– Agenda subject to change